8-K: BIO-key Receives Nasdaq Non-Compliance Notice

BIO-key International has received a notice of non-compliance from Nasdaq due to the delayed filing of its Form 10-Q for the period ended March 31, 2026.

Summary

• BIO-key International received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1).
• The non-compliance stems from the failure to timely file the Quarterly Report on Form 10-Q for the period ended March 31, 2026.
• The Nasdaq Hearing Panel will consider this failure in its ongoing determination regarding the company's continued listing on the Nasdaq Capital Market.
• A hearing regarding the company's appeal of a prior suspension determination is scheduled for June 16, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development due to the increased risk of delisting and the failure to meet basic regulatory reporting obligations.

Positives

• The company is actively engaging with the Nasdaq Hearing Panel to maintain its listing status.
• Management is taking measures to regain compliance with SEC reporting requirements.

Negatives

• Failure to file the Form 10-Q for the quarter ended March 31, 2026, on time.
• The company is currently subject to a Nasdaq delisting process, with a hearing scheduled for June 16, 2026.
• There is no assurance that the company will regain compliance or maintain its Nasdaq listing.

Risks

• Potential delisting from the Nasdaq Capital Market.
• Inability to meet SEC periodic reporting requirements.
• Uncertainty regarding the outcome of the upcoming June 16, 2026, hearing.

Future Outlook

The company is working to regain compliance with SEC reporting rules and is preparing for a hearing with the Nasdaq Panel on June 16, 2026, to address its continued listing status.

Management Comments

• The company is continuing to take all reasonable measures available to regain compliance with the Periodic Report Rule and remain listed on the Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that delays in financial reporting are a significant red flag in the cybersecurity and software sector, often signaling internal control weaknesses or liquidity constraints that can lead to severe regulatory scrutiny and potential delisting.

Comparison to Industry Standards

• Timely financial reporting is a fundamental requirement for Nasdaq-listed companies; failure to meet these deadlines is considered a serious breach of governance standards compared to industry peers.
• The company's situation is increasingly precarious compared to stable, compliant technology firms that maintain rigorous internal audit and reporting schedules.

Legal Proceedings

• The company is currently in a delisting appeal process with the Nasdaq Hearing Panel.

Stakeholder Impact

• Shareholders face increased volatility and the risk of the stock being moved to an over-the-counter market if delisting occurs.
• Creditors and partners may view the reporting delay as a sign of operational instability.

Next Steps

• Attend the Nasdaq Hearing Panel meeting on June 16, 2026.
• File the delinquent Form 10-Q for the period ended March 31, 2026.

Key Dates

Recommendation

The combination of a delayed 10-Q and an active delisting threat creates significant uncertainty and downside risk, making the stock unsuitable for conservative investors until compliance is restored.

Keywords

BIO-key, BKYI, Nasdaq, delisting, non-compliance, Form 10-Q, cybersecurity, biometric authentication